Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage

NCT03217396 is registered in ClinicalTrials.gov with Neuromed IRCCS as lead sponsor.

NCT NCT03217396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03217396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage
Lead sponsor
Neuromed IRCCS
Phase
Observational
Overall status
Recruiting
Start date
November 22, 2017
Completion date
September 30, 2027
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, amyotrophic lateral sclerosis, multiple sclerosis, parkinson disease